Inclusion Criteria:

          1. Age ≥ 18 (or age ≥ 20 as required by local regulation).

          2. Histological or cytological confirmation of advanced/metastatic solid tumors harboring
             the genetic MET alteration(s) including exon 14 deletion (METΔex14), amplification,
             fusion or activating kinase mutation, who are resistant or intolerant to standard
             therapy or for whom curative therapy is not available. Subjects must have a genetic
             MET alteration as determined by fluorescence in situ hybridization (FISH),
             quantitative polymerase chain reaction (qPCR), or next-generation sequencing
             (NGS).Local tissue-based or liquid biopsy diagnostic testing will be permitted.

          3. ECOG performance status ≤ 1.

          4. Existence of measurable or evaluable disease (according to Response evaluation
             criteria in solid tumors [RECIST v1.1] criteria).

          5. Subjects with asymptomatic primary CNS tumors or brain metastases are eligible for the
             study if they meet protocol specified criteria.

          6. Adequate organ function.

          7. Life expectancy ≥ 12 weeks.

        Exclusion Criteria:

          1. Locally advanced solid tumor that is a candidate for curative treatment through
             radical surgery and/or radiotherapy, or chemotherapy.

          2. Presence or history of any other primary malignancy other than a history of adequately
             treated basal or squamous cell carcinoma of the skin, or any adequately treated in
             situ carcinoma.

          3. Major surgery within four weeks of the start of therapy.

          4. Additional exclusion criteria for subjects with NSCLC with MET alterations: known
             oncogene drivers (ALK, ROS1, or EGFR) conferring sensitivity to targeted therapies.

          5. Additional exclusion criteria for subjects with HCC with MET alterations: liver
             dysfunction greater than Child-Pugh Class A.

          6. Clinically significant cardiovascular disease (either active or within six months
             before enrollment): myocardial infarction, unstable angina, coronary/peripheral artery
             bypass graft, symptomatic congestive heart failure (New York Heart Association
             Classification Class ≥ II), cerebrovascular accident or transient ischemic attack,
             symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac
             dysrhythmias of CTCAE version 5.0 grade ≥ 2.

          7. Any of the following cardiac criteria:

               -  Mean resting corrected QT interval (ECG interval measured from the onset of the
                  QRS complex to the end of the T wave) for heart rate (QTc) > 470 msec obtained
                  from three ECGs, using the screening clinic ECG machine-derived QTc value

               -  Any clinically important abnormalities in rhythm, conduction, or morphology of
                  resting ECG (e.g., complete left bundle branch block, third degree heart block,
                  second degree heart block, PR interval > 250 msec)

               -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic
                  events such as heart failure, congenital long QT syndrome, family history of long
                  QT syndrome, or any concomitant medication known to prolong the QT interval

          8. Known clinically significant active infections not controlled with systemic treatment
             (bacterial, fungal, viral including HIV positivity).

          9. Peripheral neuropathy ≥ Grade 2.